Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Real-time Estimate Cboe BZX Other stock markets 08:27:33 14/04/2026 pm IST			5-day change	1st Jan Change
129.42 ^USD	+2.45%		-1.19%	-8.80%

13/04	Nxera Pharma Co., Ltd. Initiates and Doses First Patient in Phase 2 Trial of Nbi-1117570 for Adults with Schizophrenia	CI
13/04	Nxera Pharma Partner Neurocrine Biosciences Doses First Patient in Phase 2 Schizophrenia Study	MT

Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08

Published on 03/09/2026 at 07:35 pm IST - Modified on 03/09/2026 at 09:06 pm IST

S&P Capital IQ

Presenter Speech
Marc Goodman (Analysts)

Thanks for joining us. I'm Marc Goodman, one of the Biopharma Analyst at Leerink, and it's great to have Neurocrine here. We have Matt Abernethy, who's the CFO;

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Neurocrine Biosciences, Inc.

13/04	Nxera Pharma Co., Ltd. Initiates and Doses First Patient in Phase 2 Trial of Nbi-1117570 for Adults with Schizophrenia	CI
13/04	Nxera Pharma Partner Neurocrine Biosciences Doses First Patient in Phase 2 Schizophrenia Study	MT
13/04	Nxera Pharma Co Ltd - Nxera Pharma's partner Neurocrine Biosciences doses first patient in phase 2 trial of NBI-1117570 for adults with schizophrenia	RE
08/04	Health Care Up as Trump Administration Boosts Medicare Rate Proposal -- Health Care Roundup	DJ
07/04	Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover	RE
07/04	The Market's Nerves of Steel
07/04	RBC Capital Adjusts Neurocrine Biosciences PT to $176 From $177, Maintains Outperform Rating	MT
07/04	Wedbush Raises Price Target on Neurocrine Biosciences to $166 From $151, Keeps Outperform Rating	MT
07/04	International Biotechnology Trust expects more M&A after Soleno deal	AN
07/04	One Final Ultimatum?
07/04	Neurocrine to acquire Soleno in multi-billion dollar deal	FW
07/04	Health Care Down on Earnings Doubts -- Health Care Roundup	DJ
07/04	Nasdaq, S&P 500 Notch 4th Consecutive Gain Amid Uncertainty Around Iran War Ceasefire	MT
07/04	Wall St ends higher as investors parse US-Iran negotiations, threats	RE
07/04	Oppenheimer Adjusts Neurocrine Biosciences Price Target to $220 From $192, Maintains Outperform Rating	MT